Current filters:


FDA sends CRL rejecting Allergan's migraine drug Levadex on quality issues


US drugmaker Allergan (NYSE: AGN) said yesterday (April 16) that the US Food and Drug Administration…

AllerganLevadexNeurologicalNorth AmericaPharmaceuticalProductionRegulation

Allergan to acquire MAP Pharmaceuticals in $958 million deal


US drugmaker Allergan (NYSE: AGN) has entered into a definitive merger agreement to acquire 100% of the…

AllerganLevadexMAP PharmaceuticalsMergers & AcquisitionsNeurologicalPharmaceutical

Migraine drug sales to grow to $5.8 billion in 2021 in major markets


Despite a decline in sales owing to the generic entry of most triptans, the launch of emerging acute…

AllerganBotoxCoLucidGenericsGloballasmiditanLevadexMAP PharmaceuticalsMarkets & MarketingPharmaceuticalResearch

FDA delay for MAP Pharma migraine drug candidate


Shares of USA-based MAP Pharmaceuticals (Nasdaq: MAPP) plunged 24% to $13.01 in early trading yesterday,…

AllerganLevadexMAP PharmaceuticalsMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalRegulation

MAP Pharma gets $20 million milestone as US FDA accepts Levadex NDA


California, USA-based MAP Pharmaceuticals (Nasdaq: MAPP) says that its New Drug Application for Levadex…

AllerganLevadexMAP PharmaceuticalsNeurologicalNorth AmericaPharmaceuticalRegulation

MAP Pharma files NDA with US regulator for Levadex in migraine


MAP Pharmaceuticals (Nasdaq: MAPP) has submitted a New Drug Application to the US Food and Drug Administration…

LevadexMAP PharmaceuticalsNeurologicalNorth AmericaPharmaceuticalRegulation

Back to top